Clinical trial
An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients…
NCT00109187 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109187 |
|---|---|
| Title | An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g |
| Official title | Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO) |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Xolair (omalizumab) |
| Enrollment | 0 |
| Start date | Jun 1, 2002 |
| Completion | Apr 1, 2003 |
| First posted | Apr 26, 2005 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: